Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells
Journal of Virology · 28.09.2023 · 97 (9)
DOI: 10.1128/jvi.01005-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 28.09.2023. Verfasst von Dakota W Goad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of North Carolina at Charlotte , Charlotte, North Carolina, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Interferon Type I, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute.
Abstract (Originalsprache)
Oncolytic virus (OV) therapy is a promising virus-based approach against various malignancies, including pancreatic ductal adenocarcinoma (PDAC). Our previous studies demonstrated that human PDAC cell lines are highly variable in their permissiveness to OVs. Mouse PDAC cell lines, which are widely used for in vivo examination of the adaptive immune responses during OV and other cancer therapies, have never been examined systematically for the impact of intertumoral heterogeneity (the differences observed between tumors in different patients) on OV virus efficacy. Here, we examined phenotypically and genotypically three commonly used allograftable mouse PDAC cell lines (C57BL6 genetic background): Panc02 (derived from chemically induced PDAC; also known as Pan02), and two cell lines originated from PDACs developed in two different KPC (Kras G12D , Trp53 R172H , and PDX-1-Cre) mouse models. Our study (i) characterized the ability of a widely used attenuated oncolytic vesicular stomatitis virus VSV-ΔM51-GFP to infect, replicate in, and kill mouse PDAC cells; (ii) examined their innate antiviral responses; (iii) compared their permissiveness to a non-attenuated VSV-Mwt-GFP and chemotherapeutic drugs; and (iv) analyzed their karyotype and exome. Mouse PDAC cell lines showed high divergence in their permissiveness to VSV-ΔM51-GFP, which negatively correlated with their abilities to mount innate antiviral responses, while all three cell lines were highly permissive to VSV-Mwt-GFP. No correlation was found between resistance to VSV-ΔM51-GFP and chemotherapy. Also, mouse PDAC cell lines showed high divergence in their karyotype and exome. The exome analysis demonstrated that more VSV-ΔM51-GFP-permissive mouse PDAC cell lines harbor mutations in multiple important antiviral genes, such as TYK2, JAK2, and JAK3. IMPORTANCE Oncolytic virus (OV) therapy is a promising virus-based approach against various malignancies, including pancreatic ductal adenocarcinoma (PDAC). Our previous studies using various human PDAC cell lines demonstrated that they are highly variable in their permissiveness to OVs. In this study, we examined phenotypically and genotypically three commonly used allograftable mouse PDAC cell lines, which are widely used for in vivo examination of the adaptive immune responses during cancer therapies. Mouse PDAC cell lines showed high divergence in their permissiveness to oncolytic vesicular stomatitis virus (VSV), which negatively correlated with their abilities to mount innate antiviral responses. Also, we discovered that more VSV-permissive mouse PDAC cell lines harbor mutations in multiple important antiviral genes, such as TYK2, JAK2, and JAK3. Our study provides essential information about three model mouse PDAC cell lines and proposes a novel platform to study OV-based therapies against different PDACs in immunocompetent mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, University of North Carolina at Charlotte , Charlotte, North Carolina, USA.
- Department of Bioinformatics and Genomics, University of North Carolina at Charlotte , Charlotte, North Carolina, USA.
- School of Data Science, University of North Carolina at Charlotte , Charlotte, North Carolina, USA.
ORCID-Profile: Valery Z Grdzelishvili
Förderung
- NCI NIH HHS
- HHS | NIH | National Cancer Institute
Zitieren
APA
Goad, D. W., Nesmelova, A. Y., Yohe, L. R., & Grdzelishvili, V. Z. (2023). Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells. Journal of Virology, 97(9). https://doi.org/10.1128/jvi.01005-23
Vancouver
Goad DW, Nesmelova AY, Yohe LR, Grdzelishvili VZ. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells. Journal of Virology. 2023;97(9). doi:10.1128/jvi.01005-23
BibTeX
@article{Goad2023,
author = {Goad, Dakota W and Nesmelova, Anna Y and Yohe, Laurel R and Grdzelishvili, Valery Z},
title = {Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells},
journal = {Journal of Virology},
year = {2023},
volume = {97},
number = {9},
doi = {10.1128/jvi.01005-23}
}
EUVIMED